ClinicalTrials.gg
CompletedNCT04956692Updated Oct 7, 2026Results posted

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

A Phase 3 interventional study of Pembrolizumab SC and Pembrolizumab IV in Non-Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 126 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Updated Oct 7, 2026Now CompletedFirst site in Russia+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
531
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung — 29 open to participants now, 48 under way, 13 of them phase 3. pembrolizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
15th of 127
531 · median 65
Started
2021
with 7 others
Phase 3
28 of 127
4 open now
Registered
85th of 127
by date
Lead sponsor
27 of 127
Merck Sharp & Dohme LLC

Among the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung, this one is the 15th largest by enrollment, is one of 8 that started in 2021, is one of 28 in phase 3, and was the 85th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

29 of the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung are open now, in 10 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate pembrolizumab (MK-3475) subcutaneous (SC) administration as the first-line therapy in the treatment of metastatic squamous and nonsquamous NSCLC by assessing the pharmacokinetics (PK), safety, and efficacy of pembrolizumab SC injection in combination with standard-of-care chemotherapy. The primary hypothesis of the study is Pembrolizumab SC is noninferior to pembrolizumab intravenous (IV) for Cycle 1 Area Under Curve (AUC) and Cycle 6 minimal concentration (Ctrough) at steady state.

Participants who discontinue study treatment after receiving the first course of 35 administrations of pembrolizumab (approximately up to 2 years) for reasons other than disease progression or intolerability, may be eligible for a second course of pembrolizumab for up to approximately 1 additional year if they have experienced radiographic disease progression per RECIST 1.1 as assessed by BICR after stopping first course treatment.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Programmed Cell Death 1 (PD1, PD-1)
  • Programmed Cell Death-Ligand 1 (PDL1, PD-L1)
  • Programmed Cell Death-Ligand 2 (PDL2, PD-L2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has pathologically (histologically or cytologically) confirmed diagnosis of squamous or nonsquamous non-small cell lung cancer (NSCLC)
  • Has Stage IV (T any, N any, M1a, M1b, or M1c - American Joint Committee on Cancer 8th Edition) squamous or nonsquamous NSCLC
  • Has confirmation that epidermal growth factor receptor (EGFR), Anaplastic lymphoma kinase (ALK), or ROS Proto-Oncogene 1, Receptor Tyrosine Kinase (ROS1)-directed therapy is not indicated in nonsquamous NSCLC as well as mixed nonsquamous/squamous NSCLC. Participants with purely squamous NSCLC do not require testing
  • Has not received prior systemic treatment for their NSCLC. Participants who received or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of metastatic disease
  • Has an (ECOG) performance score (PS) of 0 or 1
  • Male participants are eligible to participate if they agree to use as per protocol unless confirmed to be azoospermic
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of (WOCBP) or is a WOCBP who agrees of using a contraceptive method per protocol
  • Has per Version 1.1 (RECIST 1.1) as assessed by the local site investigator/radiology
  • Submit an sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated for status determination prior to randomization
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Has a known additional that is progressing or has required active treatment within the past 3 years
  • Has known central nervous system (ie, brain and/or spinal cord) and/or carcinomatous meningitis. Participants with treated may participate only if they satisfy all of the following: a) Have no evidence of new or enlarging brain metastases confirmed by post-treatment repeat brain imaging performed at least 4 weeks after pretreatment brain imaging, and b) Are neurologically stable without the need for for at least 14 days before first dose of trial treatment as per local site assessment
  • Has severe to study intervention and/or any of its
  • Has an active disease that has required systemic treatment in past 2 years
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has an active infection requiring systemic therapy
  • Has a known history of (HIV) infection and/or infection or known active infection
  • Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
  • Has symptomatic ascites or pleural effusion. A participant who is clinically stable after treatment for these conditions is eligible
  • Before the first dose of study intervention: a) Has received prior systemic cytotoxic chemotherapy for metastatic NSCLC b) Has received antineoplastic biological therapy for metastatic NSCLC c) Has had major surgery (\<3 weeks prior to first dose) d) Has received prior therapy with an anti-programmed cell death 1 (), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-programmed cell death ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor
  • Received radiation therapy to the lung that is >30 Gray within 6 months of the first dose of study intervention
  • Is expected to require any other form of antineoplastic therapy while on study
  • For participants with nonsquamous histology: Is unable to interrupt aspirin or other Non-steroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 g/day, for a 5-day period
  • For participants with nonsquamous histology: Is unable or unwilling to take folic acid or vitamin B12 supplementation
  • Has received prior radiotherapy within 2 weeks of start of study intervention or have had a history of radiation pneumonitis. Participants must have recovered from all radiation-related toxicities and not require corticosteroids. A 1-week is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease
  • Has received a live or within 30 days prior to the first dose of study intervention
  • Is currently participating in or has participated in a study of an agent or has used an investigational device within 4 weeks prior to the first dose of study intervention
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of therapy within 7 days prior the first dose of study intervention
  • Has had an allogenic tissue/solid organ transplant
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
531 participants (actual)

Study arms

  • Experimental
    Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy

    Participants receive pembrolizumab subcutaneous (SC) administration on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to \~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for squamous non-small cell lung cancer (NSCLC); PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for non-squamous NSCLC.

    Biological: Pembrolizumab SC · Drug: Paclitaxel · Drug: Nab-Paclitaxel · Drug: Carboplatin · Drug: Cisplatin · Drug: Pemetrexed

  • Active comparator
    Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy

    Participants receive pembrolizumab intravenous (IV) administration on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to \~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for squamous non-small cell lung cancer (NSCLC); PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for non-squamous NSCLC.

    Biological: Pembrolizumab IV · Drug: Paclitaxel · Drug: Nab-Paclitaxel · Drug: Carboplatin · Drug: Cisplatin · Drug: Pemetrexed

Interventions

  • SC injection

  • IV injection

    Also known as: MK-3475, KEYTRUDA®, SCH 900475

  • IV injection

    Also known as: Nov-Onxol, Onxol, Paclitaxel Novaplus, Taxol

  • IV infusion

    Also known as: Abraxane, Nanoparticle albumin-bound paclitaxel

  • IV infusion

    Also known as: Paraplatin, Paraplatin NovaPlus

  • IV infusion

    Also known as: Platinol-AQ

  • IV infusion

    Also known as: LY231514, Alimta, Pemetrexed Disodium

06

What researchers measure

Primary outcomes

  1. Cycle 1 Area Under The Curve From 0-3 Weeks (AUC 0-3wks) of Pembrolizumab

    Cycle 1 AUC0-3wks is defined as the area under the concentration-time curve for pembrolizumab in plasma over a 3-week dosing interval in Cycle 1. Each cycle is 21 days.

    Time frame: Cycle 1: predose and postdose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 2: predose day 1. Each cycle is 21 days.

  2. Cycle 6 Model-Based Minimal Concentration (Ctrough) of Pembrolizumab

    Cycle 6 model-based Ctrough is defined as the lowest concentration of pembrolizumab in plasma at the end of the dosing interval in Cycle 6, as predicted by the pharmacokinetic (PK) model based on historical intravenous pembrolizumab PK data. Each cycle is 21 days.

    Time frame: Cycle 6: predose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 7: predose day 1. Each cycle is 21 days.

Secondary outcomes

  1. Objective Response (OR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

    The OR rate is defined as the percentage of participants who achieve a confirmed complete response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR.

    Time frame: Up to approximately 5 years

  2. Cycle 1 Observed Ctrough of Pembrolizumab

    Cycle 1 observed Ctrough is defined as the lowest observed concentration of pembrolizumab in plasma at the end of the dosing interval in Cycle 1. Each cycle is 21 days.

    Time frame: Predose Cycle 2 day 1. Each cycle is 21 days.

  3. Cycle 1 Maximum Concentration (Cmax) of Pembrolizumab

    Cycle 1 Cmax is defined as the observed peak concentration of pembrolizumab in plasma over the dosing interval in Cycle 1. Each cycle is 21 days.

    Time frame: Cycle 1: predose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 2: predose day 1. Each cycle is 21 days.

  4. Cycle 6 AUC 0-3wks of Pembrolizumab

    Cycle 6 AUC0-3wks is defined as the area under the concentration-time curve for pembrolizumab in plasma over a 3-week dosing interval in Cycle 6. Each cycle is 21 days.

    Time frame: Cycle 6: predose and postdose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 7: predose day 1. Each cycle is 21 days.

  5. Cycle 6 Cmax of Pembrolizumab

    Cmax in Cycle 6 is defined as the observed peak concentration of pembrolizumab in plasma over the dosing interval in Cycle 6. Each cycle is 21 days.

    Time frame: Cycle 6: predose and postdose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 7: predose day 1. Each cycle is 21 days.

  6. Cycle 6 Observed Ctrough of Pembrolizumab

    Cycle 6 observed Ctrough is defined as the lowest observed concentration of pembrolizumab in plasma at the end of the dosing interval in Cycle 6. Each cycle is 21 days.

    Time frame: Predose Cycle 7 day 1. Each cycle is 21 days.

  7. Number of Participants Who Experienced an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 28 months

  8. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. The number of participants who discontinue study treatment due to an AE will be presented.

    Time frame: Up to approximately 25 months

  9. Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR

    PFS is defined as the time from randomization to the first documented PD per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD.

    Time frame: Up to approximately 5 years

  10. Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 5 years

  11. Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR

    For participants who show confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, duration of response is defined as the time from the first documented evidence of CR or PR until disease progression (PD) per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD.

    Time frame: Up to approximately 5 years

  12. Anti-Drug Antibodies (ADAs) Incidence After Administration of Pembrolizumab

    ADA incidence will be assessed by analyzing the development of ADAs following administration of pembrolizumab SC and pembrolizumab IV.

    Time frame: Up to approximately 26 months

07

Results

Posted May 17, 2024

Participant flow

Participant flow — Overall Study
MilestoneArm A: Pembrolizumab SC + Platinum Doublet ChemotherapyArm B: Pembrolizumab IV + Platinum Doublet Chemotherapy
Started358173
Treated356172
Completed00
Not completed358173
Withdrew: Death11547
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by parent/guardian20
Withdrew: Withdrawal by subject52
Withdrew: Ongoing in study236123

Outcome measures

PrimaryCycle 1 Area Under The Curve From 0-3 Weeks (AUC 0-3wks) of Pembrolizumab

Cycle 1 AUC0-3wks is defined as the area under the concentration-time curve for pembrolizumab in plasma over a 3-week dosing interval in Cycle 1. Each cycle is 21 days.

Time frame:
Cycle 1: predose and postdose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 2: predose day 1. Each cycle is 21 days.
Reported as:
Geometric mean · hr*µg/mL
Cycle 1 Area Under The Curve From 0-3 Weeks (AUC 0-3wks) of Pembrolizumab
hr*µg/mLArm A: Pembrolizumab SC + Platinum Doublet ChemotherapyArm B: Pembrolizumab IV + Platinum Doublet Chemotherapy
Cycle 1 Area Under The Curve From 0-3 Weeks (AUC 0-3wks) of Pembrolizumab471.33 (452.22 to 491.26)454.96 (438.54 to 471.99)
Statistical analysis
  • Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy vs Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy · t-test, 1 sided · p = <0.0001 (The one-sided p-value non-inferiority boundary is 0.02) · Geometric mean ratio (gmr): 1.04 · 96% CI 0.98 to 1.10Numerator Arm A/Denominator Arm B
PrimaryCycle 6 Model-Based Minimal Concentration (Ctrough) of Pembrolizumab

Cycle 6 model-based Ctrough is defined as the lowest concentration of pembrolizumab in plasma at the end of the dosing interval in Cycle 6, as predicted by the pharmacokinetic (PK) model based on historical intravenous pembrolizumab PK data. Each cycle is 21 days.

Time frame:
Cycle 6: predose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 7: predose day 1. Each cycle is 21 days.
Reported as:
Geometric mean · µg/mL
Cycle 6 Model-Based Minimal Concentration (Ctrough) of Pembrolizumab
µg/mLArm A: Pembrolizumab SC + Platinum Doublet ChemotherapyArm B: Pembrolizumab IV + Platinum Doublet Chemotherapy
Cycle 6 Model-Based Minimal Concentration (Ctrough) of Pembrolizumab55.93 (53.05 to 58.96)30.25 (27.93 to 32.77)
Statistical analysis
  • Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy vs Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy · t-test, 1 sided · p = <0.0001 (The one-sided p-value non-inferiority boundary is 0.03) · Geometric mean ratio (gmr): 1.85 · 94% CI 1.69 to 2.03Numerator Arm A/Denominator Arm B
SecondaryObjective Response (OR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

The OR rate is defined as the percentage of participants who achieve a confirmed complete response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR.

Time frame:
Up to approximately 5 years

Results for this outcome have not been posted.

SecondaryCycle 1 Observed Ctrough of Pembrolizumab

Cycle 1 observed Ctrough is defined as the lowest observed concentration of pembrolizumab in plasma at the end of the dosing interval in Cycle 1. Each cycle is 21 days.

Time frame:
Predose Cycle 2 day 1. Each cycle is 21 days.
Reported as:
Geometric mean · µg/mL
Cycle 1 Observed Ctrough of Pembrolizumab
µg/mLArm A: Pembrolizumab SC + Platinum Doublet ChemotherapyArm B: Pembrolizumab IV + Platinum Doublet Chemotherapy
Cycle 1 Observed Ctrough of Pembrolizumab18.36 (17.19 to 19.61)11.16 (10.49 to 11.88)
SecondaryCycle 1 Maximum Concentration (Cmax) of Pembrolizumab

Cycle 1 Cmax is defined as the observed peak concentration of pembrolizumab in plasma over the dosing interval in Cycle 1. Each cycle is 21 days.

Time frame:
Cycle 1: predose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 2: predose day 1. Each cycle is 21 days.
Reported as:
Geometric mean · µg/mL
Cycle 1 Maximum Concentration (Cmax) of Pembrolizumab
µg/mLArm A: Pembrolizumab SC + Platinum Doublet ChemotherapyArm B: Pembrolizumab IV + Platinum Doublet Chemotherapy
Cycle 1 Maximum Concentration (Cmax) of Pembrolizumab25.2 (23.8 to 26.6)58.3 (55.7 to 61.0)
SecondaryCycle 6 AUC 0-3wks of Pembrolizumab

Cycle 6 AUC0-3wks is defined as the area under the concentration-time curve for pembrolizumab in plasma over a 3-week dosing interval in Cycle 6. Each cycle is 21 days.

Time frame:
Cycle 6: predose and postdose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 7: predose day 1. Each cycle is 21 days.
Reported as:
Geometric mean · hr*µg/mL
Cycle 6 AUC 0-3wks of Pembrolizumab
hr*µg/mLArm A: Pembrolizumab SC + Platinum Doublet ChemotherapyArm B: Pembrolizumab IV + Platinum Doublet Chemotherapy
Cycle 6 AUC 0-3wks of Pembrolizumab1403.8 (1342.0 to 1468.5)952.9 (896.4 to 1013.0)
SecondaryCycle 6 Cmax of Pembrolizumab

Cmax in Cycle 6 is defined as the observed peak concentration of pembrolizumab in plasma over the dosing interval in Cycle 6. Each cycle is 21 days.

Time frame:
Cycle 6: predose and postdose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 7: predose day 1. Each cycle is 21 days.
Reported as:
Geometric mean · µg/mL
Cycle 6 Cmax of Pembrolizumab
µg/mLArm A: Pembrolizumab SC + Platinum Doublet ChemotherapyArm B: Pembrolizumab IV + Platinum Doublet Chemotherapy
Cycle 6 Cmax of Pembrolizumab65.6 (62.2 to 69.0)85.6 (80.1 to 91.4)
SecondaryCycle 6 Observed Ctrough of Pembrolizumab

Cycle 6 observed Ctrough is defined as the lowest observed concentration of pembrolizumab in plasma at the end of the dosing interval in Cycle 6. Each cycle is 21 days.

Time frame:
Predose Cycle 7 day 1. Each cycle is 21 days.
Reported as:
Geometric mean · µg/mL
Cycle 6 Observed Ctrough of Pembrolizumab
µg/mLArm A: Pembrolizumab SC + Platinum Doublet ChemotherapyArm B: Pembrolizumab IV + Platinum Doublet Chemotherapy
Cycle 6 Observed Ctrough of Pembrolizumab57.17 (52.23 to 62.58)33.19 (29.53 to 37.30)
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experience an AE will be reported.

Time frame:
Up to approximately 28 months

Results for this outcome have not been posted.

SecondaryNumber of Participants Who Discontinued Study Treatment Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. The number of participants who discontinue study treatment due to an AE will be presented.

Time frame:
Up to approximately 25 months

Results for this outcome have not been posted.

SecondaryProgression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR

PFS is defined as the time from randomization to the first documented PD per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD.

Time frame:
Up to approximately 5 years

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

OS is defined as the time from randomization to death due to any cause.

Time frame:
Up to approximately 5 years

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR) Per RECIST 1.1 as Assessed by BICR

For participants who show confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, duration of response is defined as the time from the first documented evidence of CR or PR until disease progression (PD) per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD.

Time frame:
Up to approximately 5 years

Results for this outcome have not been posted.

SecondaryAnti-Drug Antibodies (ADAs) Incidence After Administration of Pembrolizumab

ADA incidence will be assessed by analyzing the development of ADAs following administration of pembrolizumab SC and pembrolizumab IV.

Time frame:
Up to approximately 26 months

Results for this outcome have not been posted.

Adverse events

Collected over Up to approximately 19 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy118/358 (33%)132/356 (37.1%)331/356 (93%)
Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy48/173 (27.7%)62/172 (36%)160/172 (93%)
Most frequent serious events
Showing 10 of 143
Most frequent serious events
EventArm A: Pembrolizumab SC + Platinum Doublet ChemotherapyArm B: Pembrolizumab IV + Platinum Doublet Chemotherapy
PneumoniaInfections and infestations11/35610/172
AnaemiaBlood and lymphatic system disorders18/3562/172
PneumonitisRespiratory, thoracic and mediastinal disorders6/3566/172
Febrile neutropeniaBlood and lymphatic system disorders9/3565/172
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/3564/172
NeutropeniaBlood and lymphatic system disorders7/3563/172
ThrombocytopeniaBlood and lymphatic system disorders5/3563/172
AstheniaGeneral disorders5/3563/172
FatigueGeneral disorders0/3563/172
COVID-19Infections and infestations5/3563/172
Most frequent other events
Showing 10 of 39
Most frequent other events
EventArm A: Pembrolizumab SC + Platinum Doublet ChemotherapyArm B: Pembrolizumab IV + Platinum Doublet Chemotherapy
AnaemiaBlood and lymphatic system disorders188/356100/172
NeutropeniaBlood and lymphatic system disorders116/35652/172
NauseaGastrointestinal disorders98/35648/172
ThrombocytopeniaBlood and lymphatic system disorders83/35640/172
AstheniaGeneral disorders46/35631/172
Aspartate aminotransferase increasedInvestigations46/35629/172
Decreased appetiteMetabolism and nutrition disorders60/35625/172
DiarrhoeaGastrointestinal disorders59/35623/172
ConstipationGastrointestinal disorders57/35627/172
Alanine aminotransferase increasedInvestigations46/35626/172

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm A: Pembrolizumab SC + Platinum Doublet ChemotherapyArm B: Pembrolizumab IV + Platinum Doublet ChemotherapyTotal
Mean64.1 ± 8.665.6 ± 9.264.6 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Pembrolizumab SC + Platinum Doublet ChemotherapyArm B: Pembrolizumab IV + Platinum Doublet ChemotherapyTotal
Female10147148
Male257126383
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Pembrolizumab SC + Platinum Doublet ChemotherapyArm B: Pembrolizumab IV + Platinum Doublet ChemotherapyTotal
Hispanic or Latino502777
Not Hispanic or Latino307146453
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Pembrolizumab SC + Platinum Doublet ChemotherapyArm B: Pembrolizumab IV + Platinum Doublet ChemotherapyTotal
American Indian or Alaska Native639
Asian7232104
Native Hawaiian or Other Pacific Islander000
Black or African American8311
White232113345
More than one race241438
Unknown or Not Reported16824
08

Study locations

126 sites
  • St. Bernards Medical Center ( Site 0103)
    Jonesboro, Arkansas 72401, United States
  • St Joseph Heritage Healthcare-Oncology ( Site 0102)
    Fullerton, California 92835, United States
  • Cancer Blood and Specialty Clinic ( Site 0105)
    Los Alamitos, California 90720, United States
  • PIH Health Hematology Medical Oncology ( Site 0106)
    Whittier, California 90602, United States
  • Holy Cross Hospital ( Site 0017)
    Fort Lauderdale, Florida 33308, United States
  • Memorial Regional Hospital-Memorial Cancer Institute ( Site 0104)
    Hollywood, Florida 33021, United States
  • Advent Health ( Site 0013)
    Orlando, Florida 32804, United States
  • Fort Wayne Medical Oncology and Hematology ( Site 0101)
    Fort Wayne, Indiana 46804, United States
  • Baptist Health Lexington ( Site 0099)
    Lexington, Kentucky 40503, United States
  • St Luke's Hospital - Kansas City ( Site 0033)
    Kansas City, Missouri 64111, United States
  • St. Vincent Frontier Cancer Center ( Site 0058)
    Billings, Montana 59102, United States
  • Montefiore Medical Center [Bronx, NY] ( Site 0040)
    The Bronx, New York 10461, United States
  • The University of Tennessee Medical Center ( Site 0050)
    Knoxville, Tennessee 37920, United States
  • Tennessee Oncology ( Site 0051)
    Nashville, Tennessee 37203, United States
  • Oncology Consultants, PA ( Site 0052)
    Houston, Texas 77030, United States
  • Millennium Physicians - Oncology ( Site 0097)
    Houston, Texas 77090, United States
  • Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care ( Site 0100)
    Blacksburg, Virginia 24060, United States
  • West Virginia University ( Site 0056)
    Morgantown, West Virginia 26506, United States
  • HOSPITAL EVANGÉLICO DE CACHOEIRO DE ITAPEMIRIM ( Site 0307)
    Cachoeiro de Itapemirim, Espírito Santo 29308-065, Brazil
  • Hospital Sao Vicente de Paulo ( Site 0311)
    Passo Fundo, Rio Grande do Sul 99010-080, Brazil
  • Instituto Joinvilense de Hematologia e Oncologia ( Site 0308)
    Joinville, Santa Catarina 89201260, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto ( Site 0305)
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0304)
    São Paulo, São Paulo 04014-002, Brazil
  • Nouvel Hôpital Civil (NHC) ( Site 1018)
    Strasbourg, Bas-Rhin 67091, France
  • CHU Limoges CHU Dupuytren ( Site 1011)
    Limoges, Haute-Vienne 87042, France
  • Hôpital Foch ( Site 1019)
    Suresnes, Hauts-de-Seine 92150, France
  • Institut Regional du Cancer de Montpellier - ICM ( Site 1003)
    Montpellier, Herault 34298, France
  • Centre Hospitalier Sud Réunion ( Site 1020)
    Saint-Pierre, La Reunion 97448, France
  • Hopital Guillaume & Rene Laennec ( Site 1007)
    Saint-Herblain, Loire-Atlantique 44800, France
  • Centre Hospitalier de Pau ( Site 1016)
    Pau, Pyrenees-Atlantiques 64000, France
  • CHU de Rouen ( Site 1013)
    Rouen, Seine-Maritime 76031, France
  • Hopital Cochin ( Site 1002)
    Paris, 75014, France
  • Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0602)
    Guatemala City, 01010, Guatemala
  • Clinica Privada Dr. Rixci Ramirez ( Site 0601)
    Guatemala City, 01010, Guatemala
  • INTERVASC ( Site 0605)
    Guatemala City, 01010, Guatemala
  • Grupo Angeles SA ( Site 0604)
    Guatemala City, 01015, Guatemala
  • Centro Regional de Sub Especialidades Médicas SA ( Site 0600)
    Quetzaltenango, 09001, Guatemala
  • Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1106)
    Kecskemét, Bács-Kiskun county 6000, Hungary
  • Petz Aladar Megyei Oktato Korhaz ( Site 1110)
    Győr, Győr-Moson-Sopron 9023, Hungary
  • Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1103)
    Szolnok, Jász-Nagykun-Szolnok 5000, Hungary
  • Tudogyogyintezet Torokbalint ( Site 1105)
    Törökbálint, Pest County 2045, Hungary
  • Veszprem Megyei Tudogyogyintezet ( Site 1108)
    Farkasgyepű, Veszprém megye 8582, Hungary
  • Zala Megyei Szent Rafael Korhaz ( Site 1111)
    Zalagerszeg, Zalaegerszeg 8900, Hungary
  • Semmelweis University-Pulmonológiai Klinika ( Site 1114)
    Budapest, 1083, Hungary
  • Orszagos Koranyi Pulmonologiai Intezet ( Site 1104)
    Budapest, 1121, Hungary
  • Fujita Health University Hospital ( Site 3007)
    Toyoake, Aichi-ken 4701192, Japan
  • Ehime University Hospital ( Site 3005)
    Tōon, Ehime 791-0295, Japan
  • Kurume University Hospital ( Site 3006)
    Kurume, Fukuoka 830-0011, Japan
  • National Hospital Organization Hokkaido Cancer Center ( Site 3014)
    Sapporo, Hokkaido 003-0804, Japan
  • Kanazawa University Hospital ( Site 3004)
    Kanazawa, Ishikawa-ken 920-8641, Japan
  • Kanagawa Cardiovascular and Respiratory Center ( Site 3003)
    Yokohama, Kanagawa 236-0051, Japan
  • Miyagi Cancer Center ( Site 3000)
    Natori-shi, Miyagi 981-1293, Japan
  • Sendai Kousei Hospital ( Site 3015)
    Sendai, Miyagi 980-0873, Japan
  • Kurashiki Central Hospital ( Site 3013)
    Kurashiki, Okayama-ken 710-8602, Japan
  • Kansai Medical University Hospital ( Site 3016)
    Hirakata, Osaka 573-1191, Japan
  • National Hospital Organization Kinki-chuo Chest Medical Center ( Site 3009)
    Sakai, Osaka, Japan
  • Osaka Medical and Pharmaceutical University Hospital ( Site 3017)
    Takatsuki, Osaka 569-8686, Japan
  • Chiba University Hospital ( Site 3008)
    Chiba, 260-8677, Japan
  • National Hospital Organization Kyushu Medical Center ( Site 3001)
    Fukuoka, 810-8563, Japan
  • National Hospital Organization Kyushu Cancer Center ( Site 3002)
    Fukuoka, 811-1395, Japan
  • Okayama University Hospital ( Site 3012)
    Okayama, 7008558, Japan
  • Osaka International Cancer Institute ( Site 3018)
    Osaka, 541-8567, Japan
  • Tokushima University Hospital ( Site 3019)
    Tokushima, 770-8503, Japan
  • Juntendo University Hospital ( Site 3011)
    Tokyo, 113-8431, Japan
  • Showa University Hospital ( Site 3010)
    Tokyo, 142-8666, Japan
  • Hospital Nacional Carlos Alberto Seguin Escobedo ESSALUD ( Site 0704)
    Arequipa, Ariqipa 04001, Peru
  • Clínica Peruano-Americana de Trujillo ( Site 0701)
    Trujillo, La Libertad 13007, Peru
  • Oncosalud ( Site 0706)
    Lima, Muni Metro de Lima 15036, Peru
  • Clinica Internacional Sede San Borja ( Site 0705)
    Lima, 15036, Peru
  • Instituto Nacional de Enfermedades Neoplasicas ( Site 0703)
    Lima, 15038, Peru
  • Hospital Nacional Cayetano Heredia ( Site 0700)
    Lima, 15102, Peru
  • Przychodnia Lekarska KOMED ( Site 1202)
    Konin, Greater Poland Voivodeship 62-500, Poland
  • Centrum Onkologii im prof Franciszka Lukaszczyka ( Site 1201)
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-796, Poland
  • Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1206)
    Siedlce, Masovian Voivodeship 08-110, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
    Warsaw, Masovian Voivodeship 02-781, Poland
  • Centrum Pulmonologii i Torakochirurgii w Bystrej ( Site 1205)
    Bystra, Silesian Voivodeship 43-360, Poland
  • Szpital Wojewodzki im. Mikolaja Kopernika ( Site 1200)
    Koszalin, West Pomeranian Voivodeship 75-581, Poland
  • Cardiomed SRL Cluj-Napoca ( Site 1313)
    Cluj-Napoca, Cluj 400015, Romania
  • Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 1303)
    Cluj-Napoca, Cluj 400015, Romania
  • SC Radiotherapy Center Cluj SRL ( Site 1307)
    Comuna Floresti, Cluj 407280, Romania
  • S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1304)
    Craiova, Dolj 200347, Romania
  • Centrul de Oncologie Oncolab-Medical Oncology ( Site 1312)
    Craiova, Dolj 200385, Romania
  • Spitalul Municipal Ploiesti ( Site 1308)
    Ploieşti, Prahova 100337, Romania
  • Policlinica Oncomed SRL ( Site 1302)
    Timișoara, Timiș County 300239, Romania
  • S.C.Focus Lab Plus S.R.L ( Site 1301)
    Bucharest, 022548, Romania
  • Spitalul Universitar de Urgenta Bucuresti ( Site 1305)
    Bucharest, 050098, Romania
  • SPBU Clinic of Advanced medical technologies n.a. N. I. Pirogov ( Site 1406)
    Saint Petersburg, Sankt-Peterburg 190103, Russia
  • National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 1407)
    Saint Petersburg, Sankt-Peterburg 197758, Russia
  • Saint-Petersburg Scientific-Practical Center of Specialized Kinds of Medical Care (o) ( Site 1424)
    Saint Petersburg, Sankt-Peterburg 197758, Russia
  • Republican Clinical Oncology Dispensary-Chemotherapy #1 ( Site 1425)
    Kazan', Tatarstan, Respublika 420029, Russia
  • SPb SBHI City Clinical Oncological Dispensary ( Site 1409)
    Saint Petersburg, 198255, Russia
  • Wits Clinical Research ( Site 1510)
    Johannesburg, Gauteng 2193, South Africa
  • Steve Biko Academic Hospital ( Site 1506)
    Pretoria, Gauteng 0002, South Africa
  • Marry Potter Oncology Centre ( Site 1502)
    Pretoria, Gauteng 0181, South Africa
  • Sandton Oncology Medical Group PTY LTD ( Site 1505)
    Sandton, Gauteng 2196, South Africa
  • Chris Hani Baragwanath Academic Hospital-Wits Clinical Research Bara ( Site 1513)
    Soweto, Gauteng 2013, South Africa
  • The Oncology Centre ( Site 1507)
    Durban, Limpopo 4001, South Africa
  • Cape Town Oncology Trials Pty Ltd ( Site 1500)
    Kraaifontein, Western Cape 7570, South Africa
  • Chungnam National University Hospital ( Site 2002)
    Daejeon, Chungcheongnam-do 35015, South Korea
  • Chonnam National University Hwasun Hospital-Pulmonology ( Site 2000)
    Hwasun, Jeonranamdo 58128, South Korea

Showing the first 100 of 126 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Apr 2023, 19 months.

Results were first posted in May 2024, 1 year 1 month after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 19 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Aug 2026, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2021
First posted
Jul 9, 2021
StartActual
Aug 5, 2021
Primary completionActual
Apr 4, 2023
CompletionActual
Aug 24, 2026was Oct 2026
Results first posted
May 17, 2024
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 7, 2026
Sites
43 sites added, 43 sites removed — first site in Russia; no longer in Russian Federation
Show 43 added (6 Poland, 6 Ukraine, 5 Hungary, 5 Japan, 5 Russia, 4 Brazil, 4 Guatemala, 4 Romania, 1 United States, 1 Peru, 1 South Korea, 1 Taiwan)
  • Montefiore Medical Center [Bronx, NY] ( Site 0040) · The Bronx, United States
  • HOSPITAL EVANGÉLICO DE CACHOEIRO DE ITAPEMIRIM ( Site 0307) · Cachoeiro de Itapemirim, Brazil
  • Hospital Sao Vicente de Paulo ( Site 0311) · Passo Fundo, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto ( Site 0305) · São José do Rio Preto, Brazil
  • Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0304) · São Paulo, Brazil
  • Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0602) · Guatemala City, Guatemala
  • Clinica Privada Dr. Rixci Ramirez ( Site 0601) · Guatemala City, Guatemala
  • INTERVASC ( Site 0605) · Guatemala City, Guatemala
  • Grupo Angeles SA ( Site 0604) · Guatemala City, Guatemala
  • Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1106) · Kecskemét, Hungary
  • Petz Aladar Megyei Oktato Korhaz ( Site 1110) · Győr, Hungary
  • Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1103) · Szolnok, Hungary
  • Tudogyogyintezet Torokbalint ( Site 1105) · Törökbálint, Hungary
  • Veszprem Megyei Tudogyogyintezet ( Site 1108) · Farkasgyepű, Hungary
  • Fujita Health University Hospital ( Site 3007) · Toyoake, Japan
  • Ehime University Hospital ( Site 3005) · Tōon, Japan
  • Kanazawa University Hospital ( Site 3004) · Kanazawa, Japan
  • Miyagi Cancer Center ( Site 3000) · Natori-shi, Japan
  • Kurashiki Central Hospital ( Site 3013) · Kurashiki, Japan
  • Oncosalud ( Site 0706) · Lima, Peru
  • Przychodnia Lekarska KOMED ( Site 1202) · Konin, Poland
  • Centrum Onkologii im prof Franciszka Lukaszczyka ( Site 1201) · Bydgoszcz, Poland
  • Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1206) · Siedlce, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( · Warsaw, Poland
  • Centrum Pulmonologii i Torakochirurgii w Bystrej ( Site 1205) · Bystra, Poland
  • Szpital Wojewodzki im. Mikolaja Kopernika ( Site 1200) · Koszalin, Poland
  • Spitalul Municipal Ploiesti ( Site 1308) · Ploieşti, Romania
  • Policlinica Oncomed SRL ( Site 1302) · Timișoara, Romania
  • S.C.Focus Lab Plus S.R.L ( Site 1301) · Bucharest, Romania
  • Spitalul Universitar de Urgenta Bucuresti ( Site 1305) · Bucharest, Romania
  • …and 13 more on the registry record
Show 43 removed
  • Montefiore Medical Center [Bronx, NY] ( Site 0040) · Bronx, United States
  • HOSPITAL EVANGÉLICO DE CACHOEIRO DE ITAPEMIRIM ( Site 0307) · Cachoeiro de Itapemirim, Brazil
  • Hospital Sao Vicente de Paulo ( Site 0311) · Passo Fundo, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto ( Site 0305) · Sao Jose do Rio Preto, Brazil
  • Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0304) · São Paulo, Brazil
  • Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0602) · Guatemala, Guatemala
  • Clinica Privada Dr. Rixci Ramirez ( Site 0601) · Guatemala, Guatemala
  • INTERVASC ( Site 0605) · Guatemala, Guatemala
  • Grupo Angeles SA ( Site 0604) · Guatemala, Guatemala
  • Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1106) · Kecskemét, Hungary
  • Petz Aladar Megyei Oktato Korhaz ( Site 1110) · Gyor, Hungary
  • Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1103) · Szolnok, Hungary
  • Tudogyogyintezet Torokbalint ( Site 1105) · Torokbalint, Hungary
  • Veszprem Megyei Tudogyogyintezet ( Site 1108) · Farkasgyepu, Hungary
  • Fujita Health University Hospital ( Site 3007) · Toyoake, Japan
  • Ehime University Hospital ( Site 3005) · Toon, Japan
  • Kanazawa University Hospital ( Site 3004) · Kanazawa, Japan
  • Miyagi Cancer Center ( Site 3000) · Natori, Japan
  • Kurashiki Central Hospital ( Site 3013) · Kurashiki, Japan
  • Chungnam National University Hospital ( Site 2002) · Daejeon, Korea, Republic of
  • Oncosalud ( Site 0706) · Lima, Peru
  • Centrum Onkologii im prof Franciszka Lukaszczyka ( Site 1201) · Bydgoszcz, Poland
  • Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1206) · Siedlce, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( · Warszawa, Poland
  • Centrum Pulmonologii i Torakochirurgii w Bystrej ( Site 1205) · Bystra, Poland
  • Przychodnia Lekarska KOMED ( Site 1202) · Konin, Poland
  • Szpital Wojewodzki im. Mikolaja Kopernika ( Site 1200) · Koszalin, Poland
  • Spitalul Municipal Ploiesti ( Site 1308) · Ploiesti, Romania
  • Policlinica Oncomed SRL ( Site 1302) · Timisoara, Romania
  • S.C.Focus Lab Plus S.R.L ( Site 1301) · Bucuresti, Romania
  • …and 13 more on the registry record
Oct 7, 2026
Study completion
Oct 14, 2026→Aug 24, 2026 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Active, not recruiting→Completed
    43 sites added, 43 sites removed — first site in Russia; no longer in Russian Federation
    Show 43 added (6 Poland, 6 Ukraine, 5 Hungary, 5 Japan, 5 Russia, 4 Brazil, 4 Guatemala, 4 Romania, 1 United States, 1 Peru, 1 South Korea, 1 Taiwan)
    • Montefiore Medical Center [Bronx, NY] ( Site 0040) · The Bronx, United States
    • HOSPITAL EVANGÉLICO DE CACHOEIRO DE ITAPEMIRIM ( Site 0307) · Cachoeiro de Itapemirim, Brazil
    • Hospital Sao Vicente de Paulo ( Site 0311) · Passo Fundo, Brazil
    • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto ( Site 0305) · São José do Rio Preto, Brazil
    • Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0304) · São Paulo, Brazil
    • Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0602) · Guatemala City, Guatemala
    • Clinica Privada Dr. Rixci Ramirez ( Site 0601) · Guatemala City, Guatemala
    • INTERVASC ( Site 0605) · Guatemala City, Guatemala
    • Grupo Angeles SA ( Site 0604) · Guatemala City, Guatemala
    • Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1106) · Kecskemét, Hungary
    • Petz Aladar Megyei Oktato Korhaz ( Site 1110) · Győr, Hungary
    • Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1103) · Szolnok, Hungary
    • Tudogyogyintezet Torokbalint ( Site 1105) · Törökbálint, Hungary
    • Veszprem Megyei Tudogyogyintezet ( Site 1108) · Farkasgyepű, Hungary
    • Fujita Health University Hospital ( Site 3007) · Toyoake, Japan
    • Ehime University Hospital ( Site 3005) · Tōon, Japan
    • Kanazawa University Hospital ( Site 3004) · Kanazawa, Japan
    • Miyagi Cancer Center ( Site 3000) · Natori-shi, Japan
    • Kurashiki Central Hospital ( Site 3013) · Kurashiki, Japan
    • Oncosalud ( Site 0706) · Lima, Peru
    • Przychodnia Lekarska KOMED ( Site 1202) · Konin, Poland
    • Centrum Onkologii im prof Franciszka Lukaszczyka ( Site 1201) · Bydgoszcz, Poland
    • Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1206) · Siedlce, Poland
    • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( · Warsaw, Poland
    • Centrum Pulmonologii i Torakochirurgii w Bystrej ( Site 1205) · Bystra, Poland
    • Szpital Wojewodzki im. Mikolaja Kopernika ( Site 1200) · Koszalin, Poland
    • Spitalul Municipal Ploiesti ( Site 1308) · Ploieşti, Romania
    • Policlinica Oncomed SRL ( Site 1302) · Timișoara, Romania
    • S.C.Focus Lab Plus S.R.L ( Site 1301) · Bucharest, Romania
    • Spitalul Universitar de Urgenta Bucuresti ( Site 1305) · Bucharest, Romania
    • …and 13 more on the registry record
    Show 43 removed
    • Montefiore Medical Center [Bronx, NY] ( Site 0040) · Bronx, United States
    • HOSPITAL EVANGÉLICO DE CACHOEIRO DE ITAPEMIRIM ( Site 0307) · Cachoeiro de Itapemirim, Brazil
    • Hospital Sao Vicente de Paulo ( Site 0311) · Passo Fundo, Brazil
    • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto ( Site 0305) · Sao Jose do Rio Preto, Brazil
    • Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0304) · São Paulo, Brazil
    • Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0602) · Guatemala, Guatemala
    • Clinica Privada Dr. Rixci Ramirez ( Site 0601) · Guatemala, Guatemala
    • INTERVASC ( Site 0605) · Guatemala, Guatemala
    • Grupo Angeles SA ( Site 0604) · Guatemala, Guatemala
    • Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1106) · Kecskemét, Hungary
    • Petz Aladar Megyei Oktato Korhaz ( Site 1110) · Gyor, Hungary
    • Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1103) · Szolnok, Hungary
    • Tudogyogyintezet Torokbalint ( Site 1105) · Torokbalint, Hungary
    • Veszprem Megyei Tudogyogyintezet ( Site 1108) · Farkasgyepu, Hungary
    • Fujita Health University Hospital ( Site 3007) · Toyoake, Japan
    • Ehime University Hospital ( Site 3005) · Toon, Japan
    • Kanazawa University Hospital ( Site 3004) · Kanazawa, Japan
    • Miyagi Cancer Center ( Site 3000) · Natori, Japan
    • Kurashiki Central Hospital ( Site 3013) · Kurashiki, Japan
    • Chungnam National University Hospital ( Site 2002) · Daejeon, Korea, Republic of
    • Oncosalud ( Site 0706) · Lima, Peru
    • Centrum Onkologii im prof Franciszka Lukaszczyka ( Site 1201) · Bydgoszcz, Poland
    • Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1206) · Siedlce, Poland
    • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( · Warszawa, Poland
    • Centrum Pulmonologii i Torakochirurgii w Bystrej ( Site 1205) · Bystra, Poland
    • Przychodnia Lekarska KOMED ( Site 1202) · Konin, Poland
    • Szpital Wojewodzki im. Mikolaja Kopernika ( Site 1200) · Koszalin, Poland
    • Spitalul Municipal Ploiesti ( Site 1308) · Ploiesti, Romania
    • Policlinica Oncomed SRL ( Site 1302) · Timisoara, Romania
    • S.C.Focus Lab Plus S.R.L ( Site 1301) · Bucuresti, Romania
    • …and 13 more on the registry record
    Study completion Oct 14, 2026→Aug 24, 2026 (now actual)
    + 5 other changes: identifiers, verification date, references, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04956692
Responsible party
Sponsor
First posted
Jul 9, 2021
Start date
Aug 5, 2021
Primary completion
Apr 4, 2023
Completion
Aug 24, 2026
Results posted
May 17, 2024
Last update
Oct 7, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion